BioRegenx, Inc. (BRGX)
OTCMKTS
· Delayed Price · Currency is USD
0.0108
0.00 (0.00%)
At close: Mar 5, 2026
BioRegenx Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Net Income | -18.93 | -23.05 | -3.6 | -0.08 | -4.72 | -0.78 |
| Depreciation & Amortization | 0.61 | 2.22 | 0 | - | 0 | - |
| Other Amortization | 0.04 | 0.05 | - | 0.01 | - | - |
| Asset Writedown & Restructuring Costs | 16.21 | 16.21 | - | - | 1.11 | - |
| Loss (Gain) From Sale of Investments | - | - | - | 0.04 | - | - |
| Stock-Based Compensation | 1.68 | 3.69 | 2.24 | - | 0.64 | 0.42 |
| Other Operating Activities | 0.04 | 0.03 | 0.26 | -0.04 | -0.07 | - |
| Change in Accounts Receivable | -0.04 | 0.09 | -0.02 | - | 0.35 | 0.08 |
| Change in Inventory | 0.05 | 0.11 | -0.04 | - | 0.26 | -0.81 |
| Change in Accounts Payable | 0.18 | 0.19 | -0.25 | 0.01 | -1.72 | -0.66 |
| Change in Unearned Revenue | -0.07 | -0.13 | -0.08 | - | 0.09 | -0.08 |
| Change in Other Net Operating Assets | 0.18 | 0.28 | -0.03 | - | 0.12 | 0 |
| Operating Cash Flow | -0.04 | -0.32 | -1.52 | -0.06 | -3.93 | -1.84 |
| Capital Expenditures | -0.01 | -0.19 | - | - | -0.03 | - |
| Cash Acquisitions | - | 0 | - | - | - | - |
| Sale (Purchase) of Intangibles | -0.05 | - | -0.05 | - | - | - |
| Other Investing Activities | - | - | -0.15 | - | - | - |
| Investing Cash Flow | -0.05 | -0.19 | -0.2 | - | -0.03 | - |
| Short-Term Debt Issued | - | 0.06 | - | - | - | - |
| Long-Term Debt Issued | - | 0.43 | 0.07 | 0.04 | - | 0.16 |
| Total Debt Issued | 0.15 | 0.49 | 0.07 | 0.04 | 3.08 | 0.16 |
| Long-Term Debt Repaid | - | -0.05 | -0.21 | -0 | - | -0.04 |
| Total Debt Repaid | -0.08 | -0.05 | -0.21 | -0 | -0.21 | -0.04 |
| Net Debt Issued (Repaid) | 0.07 | 0.44 | -0.14 | 0.04 | 2.87 | 0.12 |
| Issuance of Common Stock | - | - | 1.34 | - | 1.48 | - |
| Other Financing Activities | - | - | - | - | - | -0 |
| Financing Cash Flow | 0.07 | 0.44 | 1.2 | 0.04 | 4.35 | 0.12 |
| Foreign Exchange Rate Adjustments | 0 | 0 | 0.02 | - | - | - |
| Net Cash Flow | -0.02 | -0.07 | -0.49 | -0.02 | 0.39 | -1.72 |
| Free Cash Flow | -0.05 | -0.51 | -1.52 | -0.06 | -3.96 | -1.84 |
| Free Cash Flow Margin | -2.49% | -21.95% | -44.41% | -153.35% | -99.39% | -23.63% |
| Free Cash Flow Per Share | - | -0.00 | -0.00 | - | -0.11 | -0.05 |
| Cash Interest Paid | 0.08 | 0.09 | 0.1 | - | 0.06 | 0.05 |
| Levered Free Cash Flow | 0.87 | 2.05 | 0.85 | -0.69 | -2.37 | - |
| Unlevered Free Cash Flow | 1.04 | 2.18 | 0.96 | -0.69 | -2.09 | - |
| Change in Working Capital | 0.3 | 0.53 | -0.42 | 0.01 | -0.89 | -1.48 |
Source: S&P Capital IQ. Standard template. Financial Sources.